GILD vs REGN: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. GILD and REGN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined GILD and REGN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Gilead Sciences is a large biopharmaceutical company best known for its leadership in treating viral diseases, especially HIV. Its HIV franchise, anchored by widely used single-tablet regimens like Biktarvy and the long-acting prevention drug for pre-exposure prophylaxis, generates the bulk of its revenue and is a global standard of care. Gilead also has a significant presence in liver diseases, including hepatitis B and C, where its cures transformed treatment, and in COVID-19 with the antiviral remdesivir. More recently, Gilead has expanded into oncology through acquisitions, building a portfolio in cell therapy (CAR-T) and antibody-drug conjugates for cancers such as breast and bladder cancer. The company makes money by selling these prescription medicines worldwide, supported by patents and strong pricing. Headquartered in Foster City, California, Gilead generates substantial cash flow from its HIV base, pays a solid dividend, and is investing to diversify into oncology and other areas as it manages future patent expirations.

Full GILD guide

Regeneron makes money primarily through two large franchises. Dupixent, an anti-inflammatory antibody used for eczema, asthma, COPD, and other conditions, is developed and commercialized in collaboration with Sanofi, and Regeneron records its share through Sanofi collaboration revenue (about $1.6 billion in Q1 2026, up roughly 36%). Eylea and the higher-dose Eylea HD treat retinal diseases such as wet age-related macular degeneration and diabetic eye disease, generating combined U.S. net product sales of about $941 million in Q1 2026, with Eylea HD now roughly half of that mix. Libtayo in oncology and a pipeline of nearly 50 clinical candidates round out the revenue base.

Full REGN guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• GILD drivers: Dominant HIV franchise; Oncology expansion.
• REGN drivers: Dupixent keeps compounding; A deep, diversified pipeline.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Gilead is heavily dependent on its HIV franchise, so any new competition, pricing pressure, or patent expiration there is a major risk. For REGN, the clearest risk is Eylea biosimilar erosion.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick GILD if you believe its drivers more; REGN if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the GILD and REGN guides.

GILD. Gilead is valued as a mature, cash-generative biopharma with a dominant HIV base and a solid dividend, rather than a high-growth name. Investors weigh durable virology cash flows and capital return against limited overall growth and uncertainty in oncology. Reported earnings can swing with acquisition-related charges, so investors often focus on underlying product revenue and free cash flow.

REGN. Figures are approximate and tied to the asOf date; verify current numbers with a live quote before acting. Regeneron reported about 19% revenue growth and adjusted EPS of roughly $9.47 in Q1 2026, beating estimates, and authorized an additional $3 billion buyback. The mid-teens P/E reflects the market weighing strong Dupixent growth against expected Eylea biosimilar erosion.

Headline figures (approximate, early 2026): GILD shows revenue (ttm) ~$28 to 30 billion, operating margin ~thirties percent (varies with charges), net income (ttm) ~variable, affected by acquisition charges, dividend yield ~3 to 4%; REGN shows total revenue (ttm, approx) ~$14 billion, q1 2026 total revenue ~$3.6 billion (up ~19% YoY), dupixent global net sales (q1 2026) ~$4.9 billion (up ~31%), eylea + eylea hd u.s. net sales (q1 2026) ~$941 million combined.

GILD and REGN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined GILD and REGN exposure against your real portfolio. It is not an investment adviser.